Image may be NSFW.
Clik here to view.
Clik here to view.
ThinkEquity starts Sarepta at buy
ThinkEquity has initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT) with a “buy” rating and a $15 price target, citing the company’s “promising eteplirsen program, targeting a meaningful market...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
OncoGenex’s OGX-427 drug gaining investor attention
Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
HCW starts ProQR Therapeutics at buy
H.C. Wainwright has initiated coverage of ProQR Therapeutics NV (NASDAQ:PRQR) with a “buy” rating and $40 price target. The stock closed at $15.46 on Friday. Analyst Andrew Fein writes that there are...
View Article
More Pages to Explore .....
